If you were expecting news about regenerative medicine, the company EpiBone You will be surprised with their latest project in which they intend to generate bones from fats.
Our imagination has found in the animation series a blank canvas with a great facility to capture ideas of all kinds. The line between fiction and reality is increasingly blurred in the field of medicine, and to show this fact I am going to resort to the well-known anime of Dragon ball. In it, you can see how our namekian Piccolo’s favorite regenerated one of his arms within seconds.
It seemed crazy, but with the stem cell revolution many of the fictitious goals are taking a lighter color; a cell capable of differentiating itself again and giving rise to another cell on demand. To what extent can we achieve a regeneration as complex as bones from fats?
The biotech company EpiBone has taken over the world of regenerative science with stem cells. The project aims at the regeneration of bones from stem cells, taking advantage of the unique qualities of the latter.
They would start with extracting a sample of cells from the fatty tissue, choosing the stem cells, and performing a computed tomography (CT) analysis of the bone they need to design.
The result will be a mold of the bone where the cells can enter, which it will take about 3 weeks to acquire optimal functionduring maturity in the bone piece, it must be ready to be implanted.
The re-constructive revolution
Why does this company revolutionize the sector of breast reconstruction procedures? Basically because they won’t have to make a bone again, but take a bit of a part, regenerate it, and take it to another place. Thus the researchers hope that the use of immunosuppressive drugs (necessary for transplantation and autoimmune diseases) is not necessary, saving large sums of money, facilitating the process and making a greater number of cases treatable.
There will be a noticeable improvement in recognition, as it is your own DNA and not that of another individual. Insures Nina Tandom, CEO and co-founder.
The project still has a long way to goYou need federal approval, which usually takes years. Furthermore, the Fda It usually delays the process more when it comes to works with living tissues.
At the moment they are working with animals, and according to Tandon’s statements they are still 18 months away from starting human tests. If they succeed, in 2023 they would already have a solution on the market for a panorama where bone transplants top (below the bloodstains) transplants in the United States.
